These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1188 related articles for article (PubMed ID: 18487568)
1. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
3. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453 [TBL] [Abstract][Full Text] [Related]
4. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423 [TBL] [Abstract][Full Text] [Related]
5. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161 [TBL] [Abstract][Full Text] [Related]
7. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Katori H; Tsukuda M; Taguchi T Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926 [TBL] [Abstract][Full Text] [Related]
8. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937 [TBL] [Abstract][Full Text] [Related]
9. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Katori H; Tsukuda M; Watai K Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160 [TBL] [Abstract][Full Text] [Related]
10. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515 [TBL] [Abstract][Full Text] [Related]
11. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847 [TBL] [Abstract][Full Text] [Related]
12. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288 [TBL] [Abstract][Full Text] [Related]
13. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543 [TBL] [Abstract][Full Text] [Related]
15. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318 [TBL] [Abstract][Full Text] [Related]
16. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475 [TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722 [TBL] [Abstract][Full Text] [Related]
18. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114 [TBL] [Abstract][Full Text] [Related]
19. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810 [TBL] [Abstract][Full Text] [Related]
20. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]